The Biobank Integrating Longitudinal ERCP Within a Prospective Chronic Pancreatitis Cohort

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFirst People's Hospital of Hangzhou

About this trial

The Biobank Integrating Longitudinal ERCP within a Prospective Chronic Pancreatitis Cohort (BILE-CP) is a prospective longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The study plans to consecutively enroll 1,500 patients with chronic pancreatitis for long-term follow-up (scheduled every 6 months). This cohort encompasses patients across the entire disease course of chronic pancreatitis, with a particular focus on and in-depth tracking of a sub-cohort of patients undergoing ERCP treatments. During baseline and follow-up visits, researchers will collect multidimensional data from participants, including sociodemographics, diet and lifestyle, emotional status and sleep quality, clinical phenotypes and disease characteristics, ERCP intervention details, clinical laboratory and imaging examinations, continuous glucose monitoring (CGM), and traditional Chinese medicine indicators. Concurrently, multi-site biological samples will be collected, including but not limited to blood, feces, bile, saliva, tongue coating, and urine.

Eligibility criteria

Qualifiers

Age ≥ 18 years, with no sex restrictions.

Meets the diagnostic criteria for chronic pancreatitis, with a definitive diagnosis of chronic pancreatitis based on imaging, pathology, or pancreatic function tests;

Receiving medical care at the study center and willing to accept long-term follow-up management.

Able to cooperate with baseline data collection and scheduled follow-ups.

Disqualifiers

Concomitant malignancies.

Concurrent severe systemic diseases with an expected life expectancy of < 1 year.

History of major pancreatic resection or pancreaticoduodenectomy.

History of major gastrointestinal surgery.

Trial design

Treatments tested in this trial

  • This observational cohort study does not involve any interventions

Treatment groups

1,500 Participants
are divided into 1 treatment group

Sponsors and collaborators